Vaccine Adjuvants Market Worth $1.6 Billion by 2027 - Exclusive Report by MarketsandMarkets™
- In October 2021, Dynavax Technologies (US) entered into a fully funded collaboration with the US Department of Defense to conduct a Phase 2 clinical trial for a plague vaccine adjuvanted with CpG 1018.
View full press release